CADTH Pharmaceutical Reviews Update — Issue 39

See Pharmaceutical Reviews Update ― Issue 39 for important news and information regarding the Canada's Drug Agency drug review programs. Highlights from this issue include:

• updated procedures for streamlined drug class reviews.

Canada's Drug Agency Program Updates

1. Updated Procedures for Streamlined Drug Class Reviews

As previously announced, Canada's Drug Agency has created a new Formulary Management Expert Committee as a 1-year pilot program. The committee will assess various types of evaluations that may be requested by participating public payers, including nonsponsored single drug reviews, therapeutic reviews, and streamlined drug class reviews.

Canada's Drug Agency has updated the Procedures for Canada's Drug Agency Streamlined Drug Class Reviews to reflect that the Formulary Management Expert Committee will issue recommendations for these reviews and to provide additional details about the process of issuing revised reimbursement recommendations as a result of a streamlined drug class review, when appropriate. The committee will consider its first Streamlined Drug Class Review, on the topic of biologics in plaque psoriasis, in August 2023.

Canada's Drug Agency is also updating the Therapeutic Review Framework and Process and will share the revised document in fall 2023.